Get the free NDA 22-512 Approval Summary for PRADAXA - accessdata fda
Show details
This document outlines the approval process and review findings for PRADAXA, a direct thrombin inhibitor indicated for the prevention of stroke and systemic embolism in patients with non-valvular
We are not affiliated with any brand or entity on this form
Get, Create, Make and Sign nda 22-512 approval summary
Edit your nda 22-512 approval summary form online
Type text, complete fillable fields, insert images, highlight or blackout data for discretion, add comments, and more.
Add your legally-binding signature
Draw or type your signature, upload a signature image, or capture it with your digital camera.
Share your form instantly
Email, fax, or share your nda 22-512 approval summary form via URL. You can also download, print, or export forms to your preferred cloud storage service.
How to edit nda 22-512 approval summary online
In order to make advantage of the professional PDF editor, follow these steps:
1
Set up an account. If you are a new user, click Start Free Trial and establish a profile.
2
Prepare a file. Use the Add New button. Then upload your file to the system from your device, importing it from internal mail, the cloud, or by adding its URL.
3
Edit nda 22-512 approval summary. Replace text, adding objects, rearranging pages, and more. Then select the Documents tab to combine, divide, lock or unlock the file.
4
Save your file. Select it from your records list. Then, click the right toolbar and select one of the various exporting options: save in numerous formats, download as PDF, email, or cloud.
pdfFiller makes dealing with documents a breeze. Create an account to find out!
Uncompromising security for your PDF editing and eSignature needs
Your private information is safe with pdfFiller. We employ end-to-end encryption, secure cloud storage, and advanced access control to protect your documents and maintain regulatory compliance.
How to fill out nda 22-512 approval summary
How to fill out NDA 22-512 Approval Summary for PRADAXA
01
Begin by gathering all relevant information about the drug PRADAXA.
02
Start filling in the NDA 22-512 Approval Summary form with the drug's name and application number at the top.
03
Provide details on the indication for use, including the intended patient population.
04
Include a summary of the clinical trials conducted, focusing on efficacy and safety data.
05
List any significant drug interactions or contraindications.
06
Fill out the details regarding manufacturing processes and controls.
07
Provide a summary of post-marketing surveillance plans.
08
Review all sections for completeness and accuracy before submission.
Who needs NDA 22-512 Approval Summary for PRADAXA?
01
Regulatory professionals at pharmaceutical companies seeking approval for PRADAXA.
02
Healthcare providers who need to understand the approval process for the drug.
03
Researchers and clinical trial sponsors involved in the development of PRADAXA.
04
Regulatory authorities responsible for assessing drug applications.
Fill
form
: Try Risk Free
People Also Ask about
Which is safer, Eliquis or Pradaxa?
As you get older, the risk of bleeding or stroke occurring while taking Pradaxa increases. However, even with the additional risk of bleeding or stroke, sometimes this medication is the best choice for you. If you're taking Pradaxa and are bleeding often, can't control bleeds, or feel dizzy, tell your doctor.
Why is Pradaxa not preferred?
A clinical trial in Europe (the RE-ALIGN trial)1 was recently stopped because Pradaxa users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin.
What is the safest blood thinner to be on?
A 2022 study published in the Annals of Internal Medicine found apixaban to be the safest blood thinner among direct oral anticoagulants (DOACs), with the lowest risk of gastrointestinal bleeding.
When was Pradaxa approved?
Eliquis is considered a first-choice treatment for preventing stroke in people with nonvalvular atrial fibrillation and might be safer for those with kidney problems. Pradaxa, on the other hand, requires careful use in people with kidney problems and has a higher risk of stomach bleeding, especially in those over 75.
Why do doctors prefer Eliquis?
If you're taking warfarin, consider talking to your doctor about ELIQUIS for both these reasons: ELIQUIS was proven effective to reduce the risk of stroke due to atrial fibrillation (AFib) not caused by a heart valve problem. Plus, ELIQUIS had significantly less major bleeding* than warfarin.
Why is Pradaxa not preferred?
A clinical trial in Europe (the RE-ALIGN trial)1 was recently stopped because Pradaxa users were more likely to experience strokes, heart attacks, and blood clots forming on the mechanical heart valves than were users of the anticoagulant warfarin.
Is Pradaxa a high risk medication?
As you get older, the risk of bleeding or stroke occurring while taking Pradaxa increases. However, even with the additional risk of bleeding or stroke, sometimes this medication is the best choice for you. If you're taking Pradaxa and are bleeding often, can't control bleeds, or feel dizzy, tell your doctor.
For pdfFiller’s FAQs
Below is a list of the most common customer questions. If you can’t find an answer to your question, please don’t hesitate to reach out to us.
What is NDA 22-512 Approval Summary for PRADAXA?
NDA 22-512 Approval Summary for PRADAXA provides an overview of the regulatory approval details for the drug Pradaxa, including its indications, safety, and efficacy as established by the FDA.
Who is required to file NDA 22-512 Approval Summary for PRADAXA?
The sponsor of the drug, which is usually the pharmaceutical company that developed Pradaxa, is required to file the NDA 22-512 Approval Summary.
How to fill out NDA 22-512 Approval Summary for PRADAXA?
To fill out the NDA 22-512 Approval Summary, the sponsor must provide detailed information about the drug's clinical trials, manufacturing processes, labeling, and compliance with regulatory standards.
What is the purpose of NDA 22-512 Approval Summary for PRADAXA?
The purpose of NDA 22-512 Approval Summary is to document the evaluation process by which the FDA assesses the drug's safety and effectiveness before granting approval for market distribution.
What information must be reported on NDA 22-512 Approval Summary for PRADAXA?
The NDA 22-512 Approval Summary must report information such as clinical trial results, pharmacology, toxicology, manufacturing details, labeling, and any post-market surveillance plans for Pradaxa.
Fill out your nda 22-512 approval summary online with pdfFiller!
pdfFiller is an end-to-end solution for managing, creating, and editing documents and forms in the cloud. Save time and hassle by preparing your tax forms online.
Nda 22-512 Approval Summary is not the form you're looking for?Search for another form here.
Relevant keywords
Related Forms
If you believe that this page should be taken down, please follow our DMCA take down process
here
.
This form may include fields for payment information. Data entered in these fields is not covered by PCI DSS compliance.
